Multiple Myeloma

FDA-approved BiTE therapies for relapsed/refractory multiple myeloma show promising response rates, offering off-the-shelf alternatives to CAR T therapy.

The approval expands the prior indication of idecabtagene vicleucel (Abecma; Bristol Myers Squibb), which will make the drug available to patients in earlier lines.

Unlike conventional monoclonal antibodies, BsAbs possess dual binding domains that target 2 distinct antigens simultaneously.

The study authors are hopeful that this finding can help in the development of new drugs or treatments for patients with multiple myeloma.

The decision to vote in favor of idecabtagene vicleucel comes after positive phase 3 trial results demonstrating its efficacy compared with standard regimens.

Chimeric antigen receptor T-cell therapies were associated with higher incidences, grades of severity, and longer duration of cytokine release syndrome compared with bispecific antibodies.

This finding was evident in both examined groups and regardless of the patients' B-cell maturation antigen-directed therapy status.

The combination of GZ17-6.02 and bortezomib reduced of HDAC, and as a result ATG13 phosphorylation was enhanced, BAK levels increased, and BCL-XL levels were reduced.

This initiative aims to raise worldwide awareness of the disease while trying to strengthen the connection between members of the multiple myeloma community.

Michael Singel, PharmD; and Carol Ann Huff, MD, discuss how step-up dosing for bispecific antibodies has been implemented in the outpatient setting with monitoring considerations for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome to ensure patient safety.

Despite the belantamab mafodotin regimen improving overall survival in patients with relapsed or refractory multiple myeloma, the trial is ongoing to confirm the presented results.

The authors found that overall survival in patients with newly diagnosed multiple myeloma was longest for those receiving first-line autologous stem cell transplantation.

The withdrawal comes after clinical trial results failed to demonstrate the safety and efficacy of melphalan flufenamide when combined with dexamethasone.

The recommendation comes after positive phase 3 trial results in adult patients with relapsed and refractory multiple myeloma.

Currently, the safety and efficacy of linvoseltamab in adult patients with relapsed or refractory multiple myeloma is being compared to elotuzumab, pomalidomide, and dexamethasone in a phase 3 clinical trial.

Teclistamab was previously approved in October 2022 for the treatment of adult patients with relapsed or refractory multiple myeloma who received at least 4 prior therapies.

The investigators note that patients with newly diagnosed multiple melanoma who receive quadruplet treatment have unmet needs that must be further examined in future research.

Progression-free survival in the ixazomib/pegylated liposomal doxorubicin/dexamethasone group was shorter than in the ixazomib/lenalidomide/dexamethasone group.

In addition to improved progression-free survival, patients treated with this regimen also showed improved complete response or stronger and were minimal residual disease-negative.

Anthony Perissinotti, PharmD, BCOP, provides an overview of the REMS program requirements for bispecific antibodies and describes the processes, procedures, and training programs implemented at his institution.

Patients readily accepted physical interventions and referrals to oncology clinical pharmacy practitioners.

Treatment decisions should depend on the patient, their disease, and their disease progression.

Survival rates were similar between non-Hispanic African American and non-Hispanic White patients who received treatment, indicating a need to address barriers to multiple myeloma treatment and racial disparities.

Daratumumab and hyaluronidase-fihj in combination with other therapies was previously approved by the FDA in May 2020 for 8 indications in multiple myeloma.

Data support the quadruplet regimen as a new standard of care for transplant-eligible patients.

Experts discuss the impact of advances in the treatment of multiple myeloma on patient care.

There is a significant efficacy-effectiveness gap in standard-of-care regimens.

Presentations detail clinical trial results and focus on drugs in the pipeline.

2023 was an impactful year for the field of oncology pharmacy.

Not only were individuals with BMIs of 30 and higher likely to have MGUS, but those who reported heavy smoking and short sleep were also more likely to have detectable levels of MGUS.